Targeted protein degradation is a rapidly exploding drug discovery strategy that uses small
molecules to recruit disease-causing proteins for rapid destruction mainly via the ubiquitin …

Nature uses a variety of tools to mediate the flow of information in cells, many of which
control distances between key biomacromolecules. Researchers have thus generated …

The discovery of small-molecule inhibitors requires suitable binding pockets on protein
surfaces. Proteins that lack this feature are considered undruggable and require innovative …

Abstract RAS oncogenes (collectively NRAS, HRAS and especially KRAS) are among the
most frequently mutated genes in cancer, with common driver mutations occurring at codons …

Parthanatos-associated apoptosis-inducing factor (AIF) nuclease (PAAN), also known as
macrophage migration inhibitor factor (MIF), is a member of the PD-D/E (X) K nucleases that …

Macrocycles have long been recognized as useful chemical entities for medicine, with
naturally occurring and synthetic macrocycles clinically approved for use as prescription …

RAS-driven cancers comprise up to 30% of human cancers. RMC-6236 is a RAS (ON) multi-
selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type …

Molecular glues are an intriguing therapeutic modality that harness small molecules to
induce interactions between proteins that typically do not interact. However, such molecules …

For two decades, diversity-oriented synthesis (DOS) has facilitated the assembly of small-
molecule libraries comprising a variety of complex molecular architectures. Here, we …

ABSTRACT Introduction Solute carriers (SLCs) represent the largest group of membrane
transporters in the human genome. They play a central role in controlling the …